Individual therapeutic monitoring of busulfan (BU) minimizes its toxicity and improves the therapeutic outcomes during hematopoietic stem cell transplantation (HSCT). For individual dose adjustment, several blood collections are performed that are uncomfortable for patients. The aim of this pilot study was to validate a laboratory method for quantification of BU in saliva and to present the results obtained using this protocol in HSCT patients. We performed analyses of selectivity, precision and accuracy of saliva with standard concentrations of BU using ultra-high-performance liquid chromatography with diode array detection. We also determined salivary and plasmatic concentrations of BU in six HSCT patients. Saliva exhibited excellent selectivity, precision and accuracy for quantification of BU. In the patient samples, significant correlations were noted between plasmatic and salivary concentrations of BU (r = 0.97, P o0.001 in the test dose; r = 0.93, P o0.001 in the adjusted dose). Passing & Bablok regression revealed good agreement between the two methods (R 2 = 0.956 for test dose; R 2 = 0.927 for adjusted dose). In conclusion, the saliva is safe for laboratory BU measurement. The good agreement with plasma encourages further clinical studies using saliva for BU therapeutic monitoring.
INTRODUCTION
Busulfan (BU) is an alkylating agent used at high doses in combination with other chemotherapy drugs in the conditioning regimen of allogeneic hematopoietic stem cell transplantation (HSCT). IV administration of BU is preferable compared with oral administration to minimize liver toxicity and variation in drug bioavailability. 1, 2 Standard BU concentrations are calculated based on the body mass, but the risk of high toxicity with poor therapeutic outcomes can be present in several cases, exposing the transplantation to failure. 3 Individual drug monitoring based on pharmacokinetic profiles is indicated in the majority of allogeneic HSCT cases. For this monitoring, at least seven to twelve blood collections are necessary for the calculation of a target area under the concentration-time curve and the steady state concentration. 3, 4 This procedure is uncomfortable for patients who frequently exhibit anxiety and fatigue. 4 Practical analytical methods have been developed for plasma measurement of BU in blood samples, such as HPLC with electrospray ionization and tandem mass spectrometry, which is indicated for dried blood samples; 5 HPLC with UV 6 and fluorescent detections; 7 gas chromatography; 8 and gas chromatography with mass-spectrometric detection. 9, 10 In the present study, we used rapid, validated, accurate ultra-high-performance liquid chromatography with a diode array detection assay for quantification of BU in saliva.
The use of saliva as an alternative matrix for drug monitoring has been considered a suitable method given its high reproducibility and excellent correlation with plasma concentrations. 11 Moreover, saliva collection is a non-invasive, painless method that does not require specialized staff. 11 A previous study evaluated the salivary concentration of BU administered orally in HSCT pediatric patients 4 and reported a high correlation between salivary and plasmatic concentrations. The authors suggested that saliva could replace the plasma collection and processing for BU monitoring in HSCT. 4 For IV BU, to the best of our knowledge, no study has focused on the efficacy of salivary analyses for individual therapeutic monitoring in HSCT.
The aim of this pilot study was to validate a laboratory method for quantification of BU in saliva and to present the results obtained using this protocol in HSCT patients.
PATIENTS AND METHODS
This study was approved by the local ethics committee on research (#2385-15).
A statement confirming informed consent was signed by all the subjects.
Laboratorial validation of busulfan quantification in saliva
In our laboratory, we employ a routine ultra-high-performance liquid chromatography with diode array detection method for plasma quantification of BU, which was developed and validated in-house following guidelines from The National Health Surveillance Agency (ANVISA), a Brazilian regulatory agency. This method was applied to saliva samples. For standardization of laboratory steps, we used a series of saliva samples from healthy volunteers who were not under any pharmacological therapy. These samples were spiked with BU analytical standard solution (B2635, Sigma Aldrich, Saint Louis, MO, USA) at different concentrations depending on the validation test performed. The sample was prepared first by adding 0.75 mL of acetonitrile to 0.5 mL of saliva followed by homogenization and centrifugation. The supernatant was derivatized with 0.5 mL of ammonium acetate buffer (0.1 mol/L, pH 5.5) and 0.3 mL of 5% w/v sodium diethyldithiocarbamate solution before incubation for 10 min at room temperature. After adding 1 mL of ethyl acetate to the solution followed by centrifugation for 10 min at 4°C and 3000 r.p.m., 1 mL of the supernatant was dried by using nitrogen flux at 60°C. The residue was reconstituted with 0.1 mL of mobile phase under agitation for 30 s. For chromatographic separation, 4 μL of the reconstituted sample was injected into a liquid chromatography system equipped with diode array detector (254 nm) (Agilent 1290 Infinity, Agilent Technologies, Santa Clara, CA, USA) column with 2.1 × 50 mm and 1.8-μm particle size (Zorbax Eclipse Plus C18, Agilent Technologies, Santa Clara, CA, USA). Elution occurred at gradient mode, and the mobile phase was composed of acidic water (orthophosphoric acid, pH 3.0) and methanol with a 1.0 mL/min flow rate. Validation procedures were performed by assaying selectivity/specificity, precision and accuracy, calibration/linearity curve, sensitivity, stability and matrix effect.
For selectivity/specificity analysis, six samples of BU-free saliva were submitted to the method described above. Response of interfering peaks in BU retention time should be o 20% of the lower limit of quantification (LLOQ).
The linearity of the method was assessed by analyzing a calibration curve prepared by using saliva samples spiked with BU analytical standard, resulting in the following concentrations: 0.05, 0.10, 0.25, 0.50, 1.00, 2.50, 5.00 and 10.0 μg/mL. Response should be precise (20% of deviation with LLOQ and 15% to other points) and accurate (80-120% for LLOQ and 85-115% for other points). Correlation coefficient should be 40.98.
For analysis of intra-assay and inter-assay (three different days) precision and accuracy, five determinations of five different levels of BU in saliva were processed: LLOQ-0.05 μg/mL; low quality control (LQC)-0.15 μg/mL; moderate quality control (MQC)-4.00 μg/mL; high quality control (HQC)-8.00 μg/mL; and dilution quality control (DQC)-8.00 μg/mL after dilution. The accuracy should not exceed 20% of the nominal value for LLOQ and 15% for the other levels. The variation coefficient should be within 20% for the LLOQ and 15% for the other points.
BU stability in saliva was determined using three samples of LQC and HQC after different storage conditions: freeze and thaw cycles, room temperature, refrigeration, freeze and post preparative. The BU concentration in each storage condition was compared with freshly prepared samples. Samples were considered stable when deviations with the freshly prepared were within 15%.
For analysis of the saliva matrix effect on BU concentration, six different samples were spiked with LQC and HQC BU concentration only in the final moment of the sample preparation at residue reconstitution. The values obtained on these six samples were compared with standard solutions through calculations of the matrix factor. Variation coefficients of BU normalized matrix factor should not exceed 15%.
Patients
The present investigation was a prospective non-randomized, observational study involving patients attending the Bone Marrow Transplantation Center of Hospital Israelita Albert Einstein, Brazil. We invited HSCT patients with indications for BU conditioning to participate in the present study. The inclusion criteria were the following: patients of both genders, patients aged between 25 and 55 years old, and patients undergoing chemotherapy with BU at myeloablative doses. The exclusion criteria were the following: patients who previously underwent TBI or irradiation in the head and neck; patients who did not allow collection of their saliva; patients with salivary flow reduction impeding saliva collection at the baseline; patients without adequate plasmatic measurement of BU due to complications in blood collection or laboratory processing; and patients with complications during the BU conditioning that led to interruption of medication.
Saliva and plasma collection
We performed saliva and plasma collections at two distinct moments as follows: at 48 h prior to HSCT conditioning using a standard dose of 32 mg/m 2 for 45 min IV infusion (that is, test dose) and during the conditioning after individual measurement of BU dose based on the results of the test dose (that is, adjusted dose). In each condition, we performed ten collections of plasma and ten of saliva after BU infusion at baseline (0 h), 30 min, 45 min (only for the test dose), 1, 2, 3, 4, 5, 6 and 8 h.
The blood was collected (5-10 mL) in heparinized tubes and then stored at − 20°C until laboratory processing. We performed saliva collection at the same time as blood collection by using a kit (Salivette, Sarstedt, Germany) composed of a sterile tube and saliva collector with acid flavor. The patient was instructed to chew the collector, which stimulated saliva secretion. After 3 min of chewing, the accumulated saliva within the oral cavity was collected and placed into sterile tube. The sample was stored at − 20°C until laboratory processing, which was initiated in the following day.
Busulfan quantification in plasma and saliva Using the previously described laboratory protocol, BU was quantified in the saliva and plasma samples collected from patients. The following pharmacokinetic parameters for salivary and plasmatic concentrations of BU were estimated: 12 λz = individual elimination rate constant; Abbreviations: BU = busulfan; DQC = dilution quality control; HQC = high quality control; LLQ = lower limit of quantification; LQC = low quality control; MQC = moderate quality control.
a Five repetitions performed on the same day. b Five repetitions performed on three different days. Abbreviations: r 2 = regression determination coefficient; VC% = variation coefficient. t 1/2 = apparent elimination half-life time; C max = maximum concentration; AUC 0-∞ = area under the plasma drug concentration-time curve extrapolated to infinity; Vz = volume distribution based on the terminal slope; CL = clearance; Css = steady state concentration with daily dosing. These data were established for test and adjusted doses. For these measurements, we used a free add-in program for pharmacokinetic analysis using a non-compartmental model and trapezoidal analysis for IV infusion. 13 
Statistical analysis
The values are presented as the mean and s.d. values. Salivary and plasmatic concentrations of BU were compared using the t-paired statistical test. Correlations between the two concentrations were analyzed using Pearson´s correlation test. Passing & Bablok regression and Bland & Altman analysis were also performed to obtain the agreement level between salivary and plasma methods. The level of significance was 5%.
RESULTS

Performance of busulfan quantification in saliva
For the selectivity/specificity analysis, none of the samples exhibited alterations in Bu retention time, indicating no restriction on saliva samples analysis. Table 1 presents the intra-assay and inter-assay variation coefficients (%) for imprecision and accuracy of the method, which were compatible with the acceptance limits. With regard to linearity, three calibration curves were prepared, and all proved were linear with correlation coefficients ranging from 0.9996 to 0.9999 without the need for a weighting factor. Responses obtained in the curves were precise and accurate (Table 2) .
BU was stable in saliva after three freeze and thaw cycles, refrigeration for 24 h, storage at room temperature for 6 h, frozen storage for 30 days and post preparation for 24 h.
The variation coefficients obtained in matrix effect analysis were 14.5% for LQC and 8.1% for HQC. These results indicate that the saliva matrix did not affect BU concentration.
Patient characteristics
We selected six adult patients for this pilot study: three females and three males. and methotrexate (at D1, D3, D6 and D11). One patient underwent autologous HSCT and received conditioning with BU, gemcitabine, melphalan and vorinostat due to a refractory lymphoma. BU was IV administered once daily from D-5 to D-2. Target area under the curve (AUC; daily dosing) was between 4000 and 5000 μM × min. During the conditioning, all patients received prophylaxis against infection (acyclovir, fluconazole, sulfamethoxazole and trimethoprim) and against liver and central nervous system toxicity (ursacol, phenytoin and clonazepam). The clinical characteristics of the patients and the transplantation are summarized in Table 3 . During the transplantation, the main complications were renal insufficiency due polyomavirus, ulcerative esophagitis derived from herpesvirus, and neutropenic colitis. None of the patients exhibited liver or central nervous system disturbances.
Quantification of busulfan in plasma and saliva of HSCT patients The majority of the patients did not exhibit any alteration in salivary flow that might interfere with saliva collection. Only two patients experienced difficulties in secreting the minimal volume of saliva necessary for the laboratory processing (500 μL). These events were observed in the two first collections during the adjusted dose. For these patients, we asked them to chew the collector for 5 min instead of 3 min, which was sufficient for achieving the total saliva volume.
In the test dose, the BU peak in both matrices occurred at 45 min, but the BU concentrations were different (1.29 ± 0.29 μg/mL for plasma and 1.18 ± 0.26 μg/mL for saliva, P = 0.04). In the other collection periods, the plasma and salivary concentrations did not exhibit significant differences (Table 4) . The plasma and salivary BU concentration curves were very similar ( Figure 1a ) and exhibited significant correlation (Pearson's r = 0.97, 95% CI = (0.95-0.99), P o 0.001). Passing & Bablok regression revealed good agreement between the two methods (R 2 -0.956, Figure 1b ) with a reduced difference in the BU concentrations (mean (s.d.) difference = -0.008 (0.079), Figure 1c ).
In the adjusted dose, the BU peak occurred at 180 min for plasma (4.21 ± 0.74 μg/mL) and saliva (4.12 ± 1.23 μg/mL). At 30 min, the salivary concentration of BU was significantly reduced compared with its plasma concentration (P = 0.04). However, in the other periods, no significant differences were noted ( Table 4) . The BU concentration curve was also very similar between plasma Table 5 presents the pharmacokinetic parameters related to plasma and salivary BU for all the variables. The mean values in plasma were similar to those in saliva for both the test and adjusted doses.
Pharmacokinetic parameters
DISCUSSION
In this study, we validated a laboratory method for quantification of BU in saliva using ultra-high liquid chromatography. The method described here exhibited a linear calibration curve with a high correlation coefficient (r 2 = 0.99) and excellent reproducibility. The salivary matrix did not interfere with BU concentration, exhibiting stability during a period of time sufficient for laboratory processing. In addition, the time of laboratory processing was equal to that of plasma processing (~4 h). Therefore, we considered that the laboratory processing of the saliva as described in the present study is adequate for detection and quantification of BU.
After laboratory validation, we collected saliva and blood from HSCT patients for evaluation to determine whether saliva collection was feasible in patients undergoing HSCT. The saliva was collected during two periods of HSCT because we wanted to assess whether the salivary flow would be sufficient for multiple collections. We used the presence of salivary flow reduction at the baseline as an exclusion criterion; however, this event can be relatively frequent in the patients during allogeneic HSCT conditioning.
14 In fact, in the present study, four collections performed in two patients resulted in an insufficient volume of saliva due to salivary flow reduction. Our number of patients is too limited to conclude whether salivary flow reduction during HSCT conditioning can be a risk for failure in the individual monitoring of BU. However, the low frequency of insufficient saliva volume detected in the present investigation encourages the performance of a study involving a larger number of patients to better evaluate the interference of xerostomia with this protocol. It is important to mention that although the saliva volume used for analysis in the present study was at least 500 μL, it is possible to develop an adequate method for a smaller volume. In another study, the ideal saliva volume was adapted to 100 μL mainly because the majority of the patients were pediatric. 4 Saliva collection is a non-invasive and inexpensive method that does not require specialized personnel, needles or other tools, which provoke anxiety and discomfort to the patients. In addition, the saliva matrix is less complex than the plasma matrix. The saliva matrix mainly contains water (99.5%) with a small amount of protein (0.3%) and inorganic/trace elements (0.2%).
11 Therefore, given its low protein concentration, the BU detected in saliva is probably unbound to proteins, as occurs in the plasma. 15, 16 In addition, BU is highly lypophilic, 15 improving its passage through the epithelial barrier of the salivary glands for rapid secretion in saliva. 17 The lypophilicity and the low protein binding inherent to BU may explain its high distribution to other compartments, including saliva and cerebrospinal fluid.
18
The saliva composition varies in accordance with the salivary gland secretion. The parotid gland is responsible for 60% of the stimulated salivary flow and secretes saliva containing high levels of amylase and proline-rich proteins. Submandibular, sublingual and minor salivary glands are responsible for the resting salivary flow and secrete mainly mucin. 19 The curves of salivary concentrations of BU described in the present study are related to stimulated saliva and do not necessarily reflect its concentration in unstimulated saliva. In addition, patients with lymphomas and leukemia who underwent cytotoxic chemotherapy before the HSCT can exhibit long-term salivary alterations, mainly decreases in total protein, amylase, lysozyme, peroxidase and IgA and increases in albumin. 20, 21 The number of patients analyzed in the present study was small and did not allow us to conclude whether alterations in the saliva at the moment of individual monitoring could interfere with the results of the BU concentrations. It is important to conduct a study focused on the analysis of salivary components in a larger sample of HSCT patients with different primary disorders and various chemotherapy treatments and to investigate whether these variables interfere with BU measurements.
The salivary concentrations of BU detected in the present study are different from those reported by another study also assessing BU in saliva. 4 The main difference was that BU was IV administered in our study, whereas in the cited article the drug was orally administered. In addition, we selected adult patients, whereas the other study evaluated young patients. Administration route and patient age strongly influence the plasma concentration of BU, and these factors may also explain the differences observed between both salivary analyses. Particularly regarding the children, pediatric patients metabolize BU faster than adults mainly due to the rapid drug distribution (this fact is associated with the high volume of body water in children) and high clearance. 3 We did not disregard possible interference of saliva components to explain these differences given that salivary proteins in children are present in smaller amounts compared with adults. 21 The pharmacokinetic parameters of plasmatic and salivary concentrations of BU are similar. In all patients, the target AUC would be achieved regardless of whether we used the pharmacokinetic measurements calculated from salivary BU concentrations. In addition, none of the patients would exceed the BU maximum dose limit of 6000 μM/L × min for BU/Flu regimen 22 if the salivary measurements were used. These findings should be confirmed in a study with more patients, but these preliminary results suggest that salivary BU monitoring is safe for BU pharmacokinetic measurements. In summary, we have developed a robust and reliable method for quantification of BU in saliva. The high correlation with plasma measurements and the absence of disparities in the pharmacokinetic parameters encourage the use of the saliva matrix for determination of individual doses. A clinical study involving a larger sample, including children and elderly individuals with various primary diseases and clinical conditions, should be conducted to elucidate the impact of salivary flow alteration and salivary components on the analysis of BU in saliva.
